Phreesia, Inc. (NASDAQ: PHR) saw an insider sale in early April when David Linetsky, the companys President of Network Solutions, sold 8,332 shares of common stock on April 10, 2026, at $8.07 per share. The transaction totaled $67,239.
Those shares were sold as Phreesias stock traded near its 52-week low of $7.77, a price level that reflects a 64% decline in the past year. Separately, on April 9, Linetsky completed additional disposals to meet tax obligations: he sold blocks of 9,454 shares and 914 shares at $9.15 per share, for proceeds totaling $94,867.
After completing the April transactions, Linetsky directly holds 224,056 shares of Phreesia common stock and is recorded as indirectly owning 12,363 shares through his spouse.
On the corporate results front, Phreesia reported fourth-quarter fiscal 2026 revenue of $127.1 million, which narrowly outpaced the Street estimate of $126.6 million. The company also posted adjusted EBITDA of $29.4 million, beating the consensus of $28.1 million.
Despite those modest beats, several analysts have adjusted their views and price targets. Citizens lowered its recommendation to Market Perform from Market Outperform. Raymond James reduced its price target to $16, and BMO Capital cut its target to $14, citing pressure tied to the pharmaceutical advertising segment. DA Davidson also trimmed its price target to $14 while maintaining a Buy rating. KeyBanc remains an outlier, keeping an Overweight rating and a $28 price target.
Management revised fiscal 2027 revenue guidance downward by approximately 7%, attributing the cut to reduced advertising spend commitments from pharmaceutical clients. The reduced guidance and sector-specific weakness in pharmaceutical advertising were cited by some analysts as the rationale for their target reductions.
Additionally, valuation commentary in recent analysis indicates the shares are trading below estimated Fair Value, placing the stock on lists of notably undervalued names according to valuation screens. That contrast - quarter results that modestly exceeded expectations alongside guidance reductions and analyst downgrades - frames the current backdrop for insider activity and market pricing.
Summary: An insider sale by Phreesias President of Network Solutions coincided with the stock near its one-year low. The company posted slight beats on revenue and adjusted EBITDA for Q4 fiscal 2026 but lowered fiscal 2027 revenue guidance amid softer pharmaceutical advertising commitments, prompting several analyst price-target reductions even as at least one firm maintained a bullish stance.